Journal of Steroids & Hormonal Science
ISSN: 2157-7536
OPEN ACCESS Freely available online
Perspective

# Polycystic Ovarian Syndrome: A Brief Perspective

**Jack Thomson***

*Editorial office, Journal of Steroid and hormonal Science, Brussels, Belgium*

## PERSPECTIVE

Polycystic ovarian syndrome is the most common cause of hyperandrogenism and oligo-anovulation in women of reproductive age, both of which have significant psychological, social, and economic repercussions. With the knowledge that women with polycystic ovarian syndrome are susceptible to metabolic syndrome and its associated comorbidities, there has been an increase in awareness of this illness among the general public and medical community in recent years. The definition of polycystic ovarian syndrome has been disputed in professions as different as internal medicine, gynaecology, and psychiatry due to the variability of its presentation. As a result, elucidating the origins of polycystic ovarian syndrome and distinguishing primary pathological changes from subsequent environmental disturbances remains a problem for clinical and basic research experts. When compared to women who have normal menstrual cycles, women with polycystic ovary syndrome virtually invariably have some abnormal gonadotropin output. Because gonadotropin concentrations change throughout the menstrual cycle and are delivered in a pulsatile manner into the circulation, a single test of luteinizing hormone and follicle-stimulating hormone has limited diagnostic sensitivity. Thus, abnormal gonadotropin levels (an elevated amount of luteinizing hormone or an elevated ratio of luteinizing hormone to follicle-stimulating hormone) do not need to be reported in order to diagnose polycystic ovarian syndrome in ordinary clinical practise. Oligomenorrhea or amenorrhea is the most common symptoms of chronic anovulation. Anovulatory cycles can lead to uterine bleeding problems and reduced fertility. Hirsutism, acne, and male-pattern hair loss (androgenic alopecia) are cutaneous manifestations of hyperandrogenemia in polycystic ovarian syndrome, whereas acanthosis nigricans is a cutaneous sign of hyperinsulinemia. Environmental factors play a role in this complex polygenic condition (e.g., those that contribute to obesity). Many studies imply that polycystic ovary syndrome is caused by ovarian steroidogenesis and follicular development anomalies. Excessive ovarian androgen production and ovulatory dysfunction are also linked to the syndrome, which is characterised by persistently rapid gonadotropin-releasing hormone pulses, an excess of luteinizing hormone, and insufficient follicle-stimulating hormone (FSH) secretion. In addition, many women with polycystic ovary syndrome have insulin resistance, and compensatory hyperinsulinemia increases androgen bioavailability by increasing ovarian (and adrenal) androgen synthesis and decreasing sex hormone–binding globulin levels. Many genes, including those encoding gonadotropin receptors, the beta subunit of FSH, insulin receptor, differentially expressed in normal and neoplastic cells domain-containing protein, and thyroid adenoma-associated protein, have been implicated in genome-wide association studies. Women with polycystic ovarian syndrome are typically seen in clinical gynaecology for menstrual irregularities, androgen excess, and infertility. The immediate presenting complaint is the focus of treatment. Women with persistent anovulalin resistance, hyperandrogenism, and abnormal gonadotropin dynamics have become more common in the last decade. Women with polycystic ovarian syndrome have a much higher chance of developing type 2 diabetes. In comparison to age- and BMI-matched controls, both lean and obese North American women with polycystic ovarian syndrome had increased insulin resistance and reduced beta-cell activity. 31% of people in their forties have reduced glucose tolerance, and 7.5 percent have type 2 diabetes. They may also be at a higher risk of developing gestational diabetes. Polycystic ovarian syndrome is linked to central obesity, hypertension, dyslipidemia, nonalcoholic fatty liver disease, and obstructive sleep apnea, among other metabolic problems. Surrogate markers for cardiovascular disease, such as intima-media thickness in the carotid artery, calcification in the coronary artery, and C-reactive protein, are also abnormal. Despite the presence of these cardiovascular risk factors, it is unknown if women who are impacted are at an elevated risk of cardiovascular morbidity and mortality. Although there have been few investigations on ethnic differences in the presentation and prevalence of polycystic ovary syndrome, some evidence suggests that different ethnic lineages have different phenotypes. Polycystic ovary syndrome appears to be more common in African Americans than in Caucasians, with 8 percent prevalence versus 4.8 percent prevalence. Asian women have equal testosterone levels but less hirsutism than their non-Asian counterparts. Insulin resistance appears to be more common in some ethnic groups, such as Latinos, Caribbean people, and South Asian people. The fact that various ethnicities present differently shows that the aetiology of polycystic ovary syndrome is genetically determined. Premature pubertal growth in adolescents is frequently associated to the

**Correspondence to:** Jack Thomson, Editorial office, Journal of Steroid and Hormonal Science, Belgium E-mail: harmonesci@scholarcentral.org

**Received:** April 29, 2021, **Accepted:** May 05, 2021, **Published:** May 25, 2021

**Citation:** Thomson J (2021) Polycystic Ovarian Syndrome: A Brief Perspective. J steroids Horm Sci. 12:01

development of polycystic ovary syndrome later in life. Menarche in these girls is accompanied by insulin resistance, dyslipidemia, and increased androgens, all of which are symptoms of polycystic ovary syndrome. These teenagers have a substantially greater rate of ovarian hyperandrogenism than the normal population. Girls with premature pubarche who were given a gonadotropin-releasing hormone analogue stimulation had a higher increase in ovarian and adrenal androgens than girls who were not hyperandrogenic. Corticotropin stimulation has similar patterns. This observation points to aberrant 17a-hydroxylase and 17,20-lyase activities in the ovary and adrenal glands. The preferred screening test is a plasma free testosterone level above the normal adult range, as determined by a speciality laboratory. Other hyperandrogenic illnesses that require particular treatment must be separated from polycystic ovary syndrome. Ultrasonography is a useful tool in this differential diagnosis since it can reveal polycystic ovaries, which have recently been identified as one of the diagnostic criteria. Specialists take different approaches to diagnosing polycystic ovary syndrome. Polycystic ovary syndrome is a diagnosis of exclusion, according to practise guidelines. However, a positive diagnosis can be made quickly using a combination of dexamethasone suppression and cosyntropin testing. The symptoms of polycystic ovary syndrome are used to evaluate therapy options, which include oral contraceptive pill, progestins, glucocorticoids, antiandrogens, and insulin-lowering medications. Polycystic ovarian syndrome (PCOS) is a multifaceted and complex female endocrine illness that is now recognised as a significant economic health burden that is expected to rise in tandem with obesity. The creations of evidence-based diagnostic and therapeutic criteria, as well as the discovery of the disorder's natural history, causation, long-term implications, and prevention, are all future goals in the field of polycystic ovarian syndrome.